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Abstract
Background—Helicobacter pylori (H. pylori) infection has been correlated with low serum 
ferritin and iron deficiency. As a secondary analysis of a study of H. pylori reinfection, we 
investigated the association of H. pylori infection and the effect of its eradication on serum ferritin 
and iron deficiency.
Methods—Alaska Native adults undergoing esophagogastroduodenoscopy had sera collected 
and a 13C urea breath test (UBT) performed. Those H. pylori positive were treated with an 
antibiotic regimen; those who tested negative 2 months after treatment were evaluated at 4, 6, 12, 
and 24 months by UBT and serum ferritin with an immunoradiometric assay. We excluded 
persons from further analysis if they were prescribed iron by their provider.
Results—We measured serum ferritin for 241 persons; 121/241 were H. pylori positive. The 
geometric mean ferritin (GMF) for persons with and without H. pylori infection were 37 µg/L and 
50 µg/L, respectively (p=0.04). At enrollment, 19/121 H. pylori-positive persons had iron 
deficiency compared with 8/120 H. pylori negative (p=0.02). Among 66 persons tested at 24 
months, the GMF was higher at 24 months (49.6 µg/L) versus enrollment (36.5 µg/L; p=0.02). Six 
of 11 persons with iron deficiency at enrollment no longer had iron deficiency and had a higher 
GMF (p=0.02) 24 months after treatment.
Conclusions—H. pylori infection was correlated with lower serum ferritin and iron deficiency. 
After H. pylori eradication, serum ferritin increased and approximately half of persons resolved 
their iron deficiency. Testing for H. pylori infection and subsequent treatment of those positive 
could be considered in persons with unexplained iron deficiency.
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Iron is the most common micronutrient deficiency in the world and iron deficiency affects 
up to 50% of the world’s population (1, 2). Many of the adverse consequences of iron 
deficiency are associated with its most severe form, iron deficiency anemia, however iron 
deficiency without anemia has been linked to an increased risk in pregnant women of 
preterm delivery and low birth weight babies and to negative impacts on cognitive 
development in children (3–5). Helicobacter pylori (H. pylori) infection impairs iron uptake 
(6) and a number of studies have found an association between H. pylori infection and low 
serum ferritin levels or iron deficiency (7–10). Additional studies have provided evidence 
that eradication of H. pylori can increase serum ferritin levels and resolve iron deficiency, 
however some studies have shown little or no change in these outcomes after eradication 
(11–14). Both H. pylori infection and iron deficiency are common in Alaska (7, 15–17). 
Here we investigate whether H. pylori infection and cagA-positive H. pylori infection are 
associated with lower serum ferritin levels and iron deficiency in Alaska Native adults living 
in Anchorage, Alaska. In addition, we report on a subset of these persons who were found to 
have H. pylori infection and were subsequently treated and followed to investigate if 
eradication results in an increase in serum ferritin levels and a resolution of iron deficiency.
Methods
Enrollment and Twenty Four Month Follow-Up
This study is a secondary analysis of an investigation of H. pylori reinfection in Alaska 
Native adults living in an urban environment. The study design and characteristics of this 
cohort of Alaska Native adults have been previously described (18). Briefly, from 
September 1998 through December 2000, we enrolled adults scheduled for 
esophagogastroduodenoscopy (EGD) evaluation at the Alaska Native Medical Center in 
Anchorage, Alaska. We established the diagnosis of H. pylori infection by EGD evaluation 
and 13C urea breath test (UBT; Meretek Diagnostics Inc., Nashville, TN; Lafayette, CO). 
Patients found to be H. pylori negative by UBT were discontinued from the study and 
patients found to be H. pylori positive by UBT and at least one of CLO, histology, or culture 
were treated with an antibiotic regimen at the discretion of the patient’s medical provider. 
Patients who tested negative by UBT two months after treatment were eligible for 
enrollment in a 24 month follow-up study. Persons in follow-up were tested by UBT for H. 
pylori recurrence four, six, 12, and 24 months after treatment. During this time we 
considered a person negative for active H. pylori infection if they continued to have a 
negative UBT. If a participant tested positive by UBT during follow-up we considered them 
to be reinfected and they were discontinued from the study. We analyzed data from persons 
who remained H. pylori negative by UBT throughout the study period.
We did not prescribe iron supplementation to any participant because serum ferritin testing 
and diagnosis of iron deficiency were done on stored sera after study completion. We 
reviewed participant’s medical charts to see if their provider had prescribed them iron at any 
point during their time in the study. If a person was prescribed iron, we removed them from 
analysis starting at the time point of the initial prescription. We did not collect information 
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about non-prescription iron supplementation and cannot rule out that some participants may 
have been taking iron therapy on their own.
The study was approved by both the Centers for Disease Control and Prevention and Alaska 
Area Institutional Review Boards as well as the Southcentral Foundation Board of Directors. 
All participants signed informed consent to participate.
Serologic Measurement of Serum Ferritin
Each time a UBT test was performed (zero, two, four, six, 12, and 24 months post 
treatment), we also collected a serum sample, stored it at −30°C, and later tested it for serum 
ferritin by a commercial immunoradiometric assay (Quantimune Ferritin IRMA; Bio-Rad, 
Hercules CA). This assay uses 125I-labeled antibody to ferritin as the tracer and ferritin 
antibodies immobilized on polyacrylamide beads as the solid phase. All specimens were 
analyzed blindly with regard to patient identification, infection status, and time since 
treatment. We defined iron deficiency as a serum ferritin level < 12 µg/L.
H. pylori culture and cagA genotyping
During EGD, providers collected gastric biopsies from the antrum and fundus of the 
stomach. Biopsies were cultured as previously described (19). For DNA extraction, H. 
pylori cells from each plate were collected together by sweeping a 1 uL inoculating loop 
across the media. The H. pylori cells were placed in 100 uL of phosphate buffered saline and 
vortexed to create a uniform turbidity. DNA was extracted with the MagNA Pure Compact 
using the MagNA Pure Compact nucleic acid isolation kit I and DNA culture cells v3.1 
protocol (Roche Applied Science, Indianapolis, IN). This protocol uses proteinase K and a 
chaotropic salt-containing lysis buffer to lyse the cells and magnetic glass particles to collect 
the nucleic acids. H. pylori DNA was subjected to PCR analysis for presence of the cagA 
gene and the cagA empty site (indicating absence of the cag PAI) using previously described 
primers (20, 21).
Statistical analysis
Ferritin levels (µg/L) were log-transformed prior to analysis; geometric mean ferritin levels 
are reported. Mean ferritin levels were compared using a t-test (independent and paired, as 
appropriate) and the proportion with iron deficiency was compared with a likelihood ratio 
chi-square test. A generalized linear model with normal response was used to adjust for age 
class and gender when comparing ferritin levels between persons negative and positive for a 
H. pylori infection at the initial study visit. A paired t-test was used to account for the 
dependence across observations induced by measuring ferritin in the same individuals at two 
different time points. All p-values are two-sided and exact when sample size necessitated. 
All statistical tests were run in SAS version 9.2 (Cary, NC) and StatXact9 (Cytel 
Comporation, Cambridge, MA).
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Ferritin levels at enrollment
There were 317 persons recruited into the original study (18) and we measured a serum 
ferritin level from 254 (80%) of those persons; the remaining 63 persons did not have 
sufficient serum available for testing. After excluding 13 persons that had an iron 
supplement prescription documented in their medical record at the time of enrollment, 241 
persons, both positive and negative for an H. pylori infection, remained and were included in 
the analysis (Table 1). At enrollment, the geometric mean serum ferritin level (GMF) for 
females was lower than males (p<0.01). The GMF in females increased with increasing age 
class (p<0.01), but not for males (p=0.41). H. pylori infection was detected by UBT in 
121/241 (50%) persons. Females infected with H. pylori had a lower GMF than uninfected 
females (p=0.003), but this was not true for males (p=0.70). Females in the two age classes 
corresponding with likely premenopausal status (<45, 45–<55) had a lower GMF if they 
were infected with H. pylori compared with those not infected (p=0.03, for both). This was 
not true for females in the postmenopausal age class (≥ 55; p=0.47). After adjusting for age 
class and sex, persons infected with H. pylori had a lower GMF than persons not infected 
(37 µg/L vs. 50 µg/L; p=0.04). The GMF was not different in persons infected with cagA-
positive versus cagA-negative strains of H. pylori (35 µg/L vs. 60 µg/L; p=0.14).
Iron deficiency was detected in 27/241 (11%) persons (Table 1). Females were not more 
likely than males to have iron deficiency (p=.14), and there was no difference in iron 
deficiency by age class for females or males (p=0.37 and p=0.59, respectively). Females 
infected with H. pylori were more likely to have iron deficiency than uninfected females 
(p=0.008), but not for males (p=1.00). After adjusting for age class and sex, persons with a 
H. pylori infection were more likely to have iron deficiency than persons without infection 
(p=0.03). The prevalence of iron deficiency was not different in persons infected with cagA-
positive versus cagA-negative strains of H. pylori.
Ferritin levels 2 months after H. pylori antimicrobial therapy
Of 116 persons that were not prescribed iron supplementation and who had a serum ferritin 
level measured before and 2 months after H. pylori treatment, 80/116 (70%) had cleared 
their infection as determined by a negative UBT. As compared with before treatment, 2 
months after treatment neither the GMF nor the percentage of persons with iron deficiency 
changed in those with their H. pylori infection eradicated (p=0.63 and p=1.00, respectively) 
or those without successful eradication (p=0.59 and p=0.18, respectively; Table 2).
Ferritin levels among persons followed for 24 months after H. pylori eradication
Eighty-seven persons had their H. pylori infection eradicated, were followed for 24 months 
or until H. pylori reinfection, and had at least one serum tested for ferritin level after the first 
2 months. Among the persons with a ferritin level measured at enrollment and 12 and 24 
months post-treatment, the GMF had not changed significantly between enrollment and 12 
months (36.5 µg/L vs. 43.7 µg/L, respectively; p=0.26, n = 63) but was higher at 24 months 
(49.6 µg/L; p=0.02; Table 3, n = 66). Of 15 persons with iron deficiency at enrollment, 11 
had a serum ferritin level measured again at 24 months and 55% of them (95% CI: 23%–
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83%) no longer had iron deficiency. Of these same 15 persons, the GMF had not changed 
significantly between enrollment and 12 months (4.8 µg/L vs. 9.4 µg/L, respectively; 
p=0.20), but was higher at 24 months (10.8 µg/L; p=0.02).
Discussion
Recent meta-analyses concluded that H. pylori infection is associated with iron deficiency 
and iron deficiency anemia and treatment for the infection could be effective in improving 
anemia and iron stores (8, 22–25). Data from this study of Alaska Native adults living in 
urban Alaska also showed that infection with H. pylori is associated with lower iron stores 
and iron deficiency. Additionally, eradication of the H. pylori infection without known iron 
supplementation was associated with an increase in serum ferritin levels and a 50% decrease 
in the number of persons with iron deficiency.
Our results are consistent with previous data from four large studies evaluating the effect of 
H. pylori infection on iron metabolism (7, 9,10, 26). In two studies involving over 7,000 and 
over 1,800 participants, there were 13.9% and 17%, respectively, lower serum ferritin levels 
in persons infected with H. pylori than in those uninfected (9, 10). A third study of almost 
3,000 persons showed that both men and postmenopausal women infected with H. pylori 
had lower mean serum ferritin levels than uninfected persons (26). Finally, a survey of over 
2,000 sera from Alaska Native persons found an association with H. pylori seropositivity 
and low serum ferritin levels (7). Similar to our data, three of these studies also included 
data showing an increase in the prevalence of iron deficiency among H. pylori-infected 
persons (7, 9, 26).
There have been four meta-analyses published in the past two years that have investigated 
whether H. pylori eradication is effective in improving iron deficiency and/or iron 
deficiency anemia; all of them concluded that H. pylori eradication improved ferritin levels 
and could be effective in improving anemia or iron deficiency (22–25). The studies included 
in these meta-analyses differ from our study in two important ways. First, these meta-
analyses involved only patients with iron deficiency or iron deficiency anemia. As our study 
involved a secondary analysis of an investigation of H. pylori reinfection, participants 
included anyone with a documented H. pylori infection. Second, all of the studies in these 
meta-analyses were required to include iron supplementation as well as anti-H. pylori 
treatment; in our study, participants were excluded when their medical record indicated an 
iron supplement was prescribed. These two differences make it more difficult for our study 
to demonstrate a positive relationship between H. pylori eradication and improved iron 
stores when compared with these meta-analyses. However, in spite of the study design 
differences, after eradication of H. pylori, we also documented a statistically significant 
increase in serum ferritin levels and improvement of iron deficiency.
We know of six additional published studies that measure the effect of H. pylori eradication 
on serum ferritin levels without iron supplementation (11, 14,27–30).. In four of these six 
studies, authors documented an increase in serum ferritin within six months post-H. pylori 
eradication (11, 14,27, 29). Although we also saw increases in serum ferritin, it was not until 
two years after eradication. In one study conducted in Alaska Native children 7–11 years old 
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it took >14 months to see changes in iron metabolism after eradication of H. pylori even 
with iron supplementation, a finding that would be consistent with our result in adults (31). 
Although the actual mechanism is not known, one way H. pylori might negatively affect 
iron metabolism is from changes in iron absorption due to chronic gastritis (6, 32–34). Some 
studies in adults have shown that it can take many months, possibly years, to resolve 
gastritis after H. pylori eradication (35, 36). In Alaska, infection with H. pylori occurs in 
childhood and is thought to last a lifetime unless treated (7, 37–39) and two studies 
conducted in Alaskan adults showed a predominance of chronic gastritis caused by H. 
pylori.(15, 17) It is possible that H. pylori infection beginning in childhood may cause 
gastrointestinal changes, particularly atrophic gastritis, that take many months to heal after 
eradication of infection. This might contribute to the slow recovery of serum ferritin levels 
and delay the resolution of iron deficiency.
Because we also cultured and genotyped the H. pylori organisms collected as part of our 
original study, we were able to investigate how infection with cagA-positive strains of H. 
pylori affect iron stores and iron deficiency. Previous studies have shown that infection with 
a cagA-positive strain of H. pylori increases risk of gastric atrophy compared with a cagA-
negative strain (40–42). Therefore, we would speculate that infection with a cagA-positive 
strain of H. pylori could lead to even lower serum ferritin levels and increased iron 
deficiency than infection with a cagA-negative strain. However, in this study we did not see 
that relationship. The prevalence of iron deficiency at enrollment was similar in persons 
having a cagA-positive or cagA-negative H. pylori infection, However, although it did not 
reach statistical significance, GMF was lower in persons having a cagA-positive infection 
than in those with a cagA-negative infection. Two additional studies in children have 
demonstrated an association between CagA-positive strains and lower levels of serum 
ferritin, (43, 44) however, just as in our study, neither found a statistically significant 
association. Additional work on this topic is warranted.
The main limitation of this study is, except for provider-prescribed iron, not collecting 
information on factors that could influence ferritin levels such as non-prescription iron 
supplementation, diet history, blood donation, use of hormonal contraception medications, 
or acute phase reactants. However, because testing for serum ferritin was done after study 
completion, we also did not inform study participants of their iron status so did not bias their 
iron intake in that way. To our knowledge, none of these factors potentially influencing 
ferritin levels affect infection with H. pylori. Thus, we have no reason to believe any of 
these would be more prominent in our H. pylori-infected versus non-infected persons or in 
the successfully treated persons we followed for 24 months. However, we cannot rule out 
that possibility and this does not rule out the possibility of confounders, such as diet, 
affecting the relationship between H. pylori infection and ferritin levels. We also do not 
have a complete understanding of the study participant’s iron status or reason for iron 
deficiency because, except for measuring serum ferritin levels, we did not perform any other 
iron test such as iron-binding capacity, hemoglobin level, mean cell volume, or fecal occult 
blood. Finally, as we cannot ethically give antibiotics to persons without H. pylori infection 
and H. pylori eradication can lead to the loss of other microbes (45), we cannot know for 
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sure that the change in ferritin levels was completely an H. pylori–specific event and did not 
involve additional organisms.
In conclusion, the findings from this study suggest that among persons with unexplained 
iron deficiency, testing for H. pylori infection could be important. Subsequent treatment for 
those positive for the bacteria could be considered, as successful treatment and remaining 
infection free for many months may play a role in the resolution of iron deficiency.
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Table 1
Serum ferritin levels and iron deficiency at study enrollment in Alaska Native adults with and without a 





Study cohort (n=241) 42 µg/L 27 (11%)
Female (n=158) 36 µg/L 21 (13%)
  <45 years (n=70) 27 µg/L 10 (14%)
  45 –<55 years (n=47) 35 µg/L 8 (17%)
  ≥ 55 years (n=41) 60 µg/L 3 (7%)
Male (n=83) 61 µg/L 6 (7%)
  <45 years (n=37) 51 µg/L 3 (8%)
  45 –<55 years (n=22) 79 µg/L 2 (9%)
  ≥ 55 years (n=24) 63 ug/L 1 (4%)
H. pylori negativeb (n=120) 50 µg/Lc 8 (7%)d
H. pylori positiveb (n=121) 37 µg/Lc 19 (16%)d
  cagA positivee (n=95) 35 µg/Lf 15 (16%)
  cagA negative (n=10) 60 µg/Lf 1 (10%)
a




p = 0.04 H. pylori negative vs. H. pylori positive
d
p = 0.02 H. pylori negative vs. H. pylori positive
e
includes persons with both cagA positive and cagA negative colonies
f
p = 0.14 cagA. positive vs. cagA negative













Miernyk et al. Page 11
Table 2
Ferritin levels and iron deficiency in Alaska Native persons before and after eradication of Helicobacter pylori 











  Pre-treatment 35.7 µg/L 35.1 µg/L 0.94
  Post-treatmentb 34.5 µg/L 37.1 µg/L 0.77
  P-valuec 0.63 0.59
Iron Deficiencyd
  Pre-treatment 14 (18%) 5 (14%) 0.63
  Post-treatmentb 14 (18%) 8 (22%) 0.55
  P-valuec 1.00 0.18
a
persons successfully treated versus persons who failed treatment
b




serum ferritin level of <12.0 µg/L
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Table 3
Ferritin levels and iron deficiency in Alaska Native persons successfully treated for a Helicobacter pylori 
infection and followed for 24 months; Anchorage, Alaska; September, 1998 – December, 2002.




Iron deficiencyb Geometric mean
ferritin
Iron deficiency
Enrollment 36.5 µg/L (n=87) 17% (15/87) 4.8µg/L (n=15) 100% (15/15)
2 month 34.3 µg/L (n=83) 17% (14/83) 6.8 µg/L (n=14) 71% (10/14)
4 month 43.2 µg/L (n=69) 13% (9/69) 7.5 µg/L (n=10) 60% (6/10)
6 month 34.0 µg/L (n=62) 21% (13/62) 7.9 µg/L (n=10) 73% (8/11)
12 month 43.7 µg/L (n=63) 17% (11/63) 9.4 µg/L (n=11) 45 % (5/11)
24 month 49.6 µg/L (n=66) 15% (10/66) 10.8 µg/L (n=11) 55% (6/11)
a
The number of observations vary because 1) each participant did not have a serum ferritin measured at every time point and 2) participants were 
removed from further analysis at the time point they had an iron supplement prescription documented in their medical record.
b
serum ferritin level of <12.0 µg/L
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